[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1105125T1 - Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων - Google Patents

Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων

Info

Publication number
CY1105125T1
CY1105125T1 CY20061101098T CY061101098T CY1105125T1 CY 1105125 T1 CY1105125 T1 CY 1105125T1 CY 20061101098 T CY20061101098 T CY 20061101098T CY 061101098 T CY061101098 T CY 061101098T CY 1105125 T1 CY1105125 T1 CY 1105125T1
Authority
CY
Cyprus
Prior art keywords
functional
inhibitors
acetylcholinestepase
preparation
pain syndromes
Prior art date
Application number
CY20061101098T
Other languages
English (en)
Inventor
Maria Nicolodi
Federigo Sicuteri
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Publication of CY1105125T1 publication Critical patent/CY1105125T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφαρμογή αναφέρεται στη χρήση αναστολέων ακετυλοχολινεστεράσης που έχουν κεντρική δράση για τη θεραπευτική αντιμετώπιση συνδρόμων λειτουργικών (ημικρανία και πρωτογενής ινομυαλγία) και/ή οργανικών (ακρωτηριασμός, "μέλος-φάντασμα", ογκολογική ή τραυματική απονεύρωση ή αυτοάνοσο μηχανισμό) κεντρικών πόνων.
CY20061101098T 1998-09-11 2006-08-07 Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων CY1105125T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998FI000208A IT1304904B1 (it) 1998-09-11 1998-09-11 Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
PCT/EP1999/006648 WO2000015205A2 (en) 1998-09-11 1999-09-09 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes

Publications (1)

Publication Number Publication Date
CY1105125T1 true CY1105125T1 (el) 2009-11-04

Family

ID=11352669

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101098T CY1105125T1 (el) 1998-09-11 2006-08-07 Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων

Country Status (12)

Country Link
US (1) US6608088B1 (el)
EP (1) EP1112067B1 (el)
JP (1) JP3984787B2 (el)
AT (1) ATE327740T1 (el)
AU (1) AU5861799A (el)
CY (1) CY1105125T1 (el)
DE (1) DE69931640T2 (el)
DK (1) DK1112067T3 (el)
ES (1) ES2265691T3 (el)
IT (1) IT1304904B1 (el)
PT (1) PT1112067E (el)
WO (1) WO2000015205A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345803T1 (de) 2000-03-03 2006-12-15 Eisai Co Ltd Neue methoden unter verwendung von cholinesteraseinhibitoren
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
MXPA02010410A (es) * 2000-04-21 2003-04-25 Upjohn Co Tratamiento de los sindromes de fibromialgia y de fatiga cronica.
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
EP1856075A1 (en) 2005-01-25 2007-11-21 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
JP5731094B2 (ja) * 2005-02-11 2015-06-10 スティーブン・ウィルスＳｔｅｐｈｅｎ ＷＩＬＬＳ アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療
EP1871368B1 (en) * 2005-04-04 2011-06-08 Eisai R&D Management Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
WO2008006286A1 (fr) 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd Dérivés analgésiques 5,9 - méthanocyclo-octa (b) pyridine - 2 (1h) - one, leur procédé de préparation et leur utilisation
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6082250B2 (ja) 2010-02-09 2017-02-15 ザ・ジョンズ・ホプキンス・ユニバーシティー 認知機能を改善するための方法および組成物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2015078129A (ja) * 2012-02-01 2015-04-23 株式会社新日本科学 ドネペジルを含む線維筋痛症の治療剤
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010083A (en) * 1988-03-28 1991-04-23 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-methano-1,3-benzodiazocine compounds which have useful pharmaceutical utility
DE3927049A1 (de) * 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
AU8742198A (en) * 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity

Also Published As

Publication number Publication date
IT1304904B1 (it) 2001-04-05
ES2265691T3 (es) 2007-02-16
DE69931640T2 (de) 2007-03-08
JP3984787B2 (ja) 2007-10-03
WO2000015205A3 (en) 2000-08-24
DK1112067T3 (da) 2006-09-04
ATE327740T1 (de) 2006-06-15
JP2002524498A (ja) 2002-08-06
WO2000015205A2 (en) 2000-03-23
EP1112067A2 (en) 2001-07-04
EP1112067B1 (en) 2006-05-31
ITFI980208A0 (it) 1998-09-11
US6608088B1 (en) 2003-08-19
AU5861799A (en) 2000-04-03
PT1112067E (pt) 2006-09-29
DE69931640D1 (de) 2006-07-06
ITFI980208A1 (it) 2000-03-11

Similar Documents

Publication Publication Date Title
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
DK0751789T3 (da) Gel til behandling af hudsygdomme og til desinfektion af huden
CY1105834T1 (el) Χρηση παρασκευασματων για την εφαρμογη, στον κατω αναπνευστικο σωληνα αντισηπτικων παραγοντων και/ή παραγοντων που προαγουν την επουλωση των πληγων
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
PT805796E (pt) Inibidores da adesao celular
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
SE9900961D0 (sv) Novel compounds
NO954878L (no) Pyrrolderivater
SE9802208D0 (sv) Novel compounds
TR199802537T2 (xx) Peptit t�revleri.
DK0998287T3 (da) Anvendelse af levobupivacain
DK0832081T3 (da) Bicykliske-aromatiske forbindelser
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
TR199801614T2 (xx) Peptit t�revleri
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE69819539D1 (de) Antithrombotische mittel
SE9802209D0 (sv) Novel compounds
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА